An important study by F. Eun-Hyung Lee's team shows that long lived plasma cells (the source of long-term circulating antibodies) fail to establish after mRNA vaccination (even combined with SARS-CoV-2 infection). 🧵 (1/) nature.com/articles/s4159…
The longevity of antibody-mediated protection against infectious diseases rely on whether or not the vaccines can establish long lived plasma cells (LLPC) in the bone marrow. They are the source of circulating antibodies for years to decades. (2/) nature.com/articles/s4159…
The study by Nguyen et al examined the long lived and short lived plasma cells in the bone marrow in people who received COVID mRNA vaccines, tetanus and flu vaccines at various time points . They found no LLPC (PopD) specific to COVID but found PopD against tetanus and flu. (3/)
This lack of LLPC against the spike protein is also true for IgA-secreting plasma cells. IgA is an isotype of antibody that can be transported across the mucosal epithelial cells. Plasma cells secreting IgA may be present in the respiratory tract esp after infection (not tested here). (4/)
Can infection boost spike-specific LLPC in the bone marrow? The answer appears to be no. Vaccinated people who also had infection still made very little LLPC against spike. (5/)
In summary, this study shows that for some reason, vaccination against Spike with mRNA vaccine (even combined with infection) fails to establish long lived plasma cells that provide IgG against the virus long term. (6/)
Why is this? Is it the vaccine or antigen? We can test whether other vax platforms (subunit, viral vectored), routes (mucosal, epidermal) or adjuvants can overcome the limitations of establishing LLPC against spike. We may also need to modify the spike antigen to elicit LLPCs. (7/)
Note that current vaccines are still important, as they boost short-term antibody responses, restimulate memory cells, generate variant-matched immune responses...etc. But we can do better. (8/)
For example, nasal boosters given every few months may be able to maintain protective IgA in the nose and throat. Self-administration can make this easier. We need out of the box thinking to combat respiratory viruses like COVID and to prevent infection, transmission & #longCOVID (end)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Is there an association between human herpesviruses (HHVs) reactivation and Long COVID? We analyzed HHV DNA shedding in saliva and found that HHV-6 correlates with Long COVID severity. Claire Laxton, @S_Tabachnikova, Lily Cooke, Kexin Wang et al.
Our study enrolled 45 participants with LC and 45 age-sex-matched controls. Surveys and health questionnaires were used to collect symptom profiles. Note the intense levels of fatigue, pain, and other symptoms in our LC group (bottom half) throughout the days 😱 (2/)
We quantified DNA from multiple HHVs in saliva to ask a simple question: are any of these viruses more active in those with worse Long COVID? HHV-6 stood out. Higher HHV-6 levels were associated with more severe symptoms and greater functional impairment (3/)
Our new preprint by @peowenlu @SaefIzzy @weinerlabhms and colleagues shows that nasal anti-CD3 monoclonal antibody treatment can reduce neuroinflammation in a mouse model of Long COVID, even when administered at 4 weeks after infection 🧠 biorxiv.org/content/10.648…
Neuroinflammatory damage is a hallmark of Long COVID. Nasal delivery of anti-CD3 mAb induces Treg and has shown therapeutic benefit in various autoimmune and CNS models of disease. In this study, we asked whether anti-CD3 mAb can reduce damage and restore neurogenesis.
First, we tested whether anti-CD3 mAb administered nasally starting at 1 week post-infection for 4 weeks. The treatment restored microglial and astrocyte densities and reduced inflammatory cytokines.
A groundbreaking paper by @younis_sh1 et al. @stanfordimmuno provides an answer to the long-standing question about how EBV infections are linked to lupus. A short thread to explain the key findings. (1/) science.org/doi/10.1126/sc…
The authors developed a new method called EBV-seq, enabling them to overcome the barrier of studying rare cells (~25 per 10,000 B cells in lupus patients) that are infected by EBV. Note that in healthy people, only 1/10,000 B cells are EBV-infected. (2/)
First, the authors found that EBV infects autoreactive B cells that express anti-nuclear antibodies in lupus patients, but not in healthy people or in patients with multiple sclerosis. (3/)
Introducing BEACON (Bioactive Enhanced Adjuvant Chemokine Oligonucleotide Nanoparticles) to stimulate mucosal immune responses against genital #HSV infection. Awesome work led by @sachinbhag, who designed and developed BEACON to guide T and B cells (1/) biorxiv.org/content/10.110…
The BEACON nanoparticle is composed of CpG ODN (TLR9 agonist) and CXCL9 (chemokine). When applied to the vaginal mucosa, the recruitment of antiviral T cells is achieved with minimal local inflammation - much more potent than CpG or CXCL9 separately. (2/)
Intramuscular vaccines do not promote mucosal immunity. BEACON can be used as a local adjuvant to boost HSV-2 gD- or gB-specific T and B cells, preventing not only disease/death but also blocking viral load in both vaginal tissue and dorsal root ganglia (🚫latency)(3/)👇🏼
A fascinating new study by Vishnu Shankar et al. @stanfordimmuno shows that oxidative stress is a shared characteristic of ME/CFS and Long COVID in lymphocytes due to inability to clear reactive oxygen species. This happens in sex-specific manner. (1/) pnas.org/doi/abs/10.107…
Females show higher mtROS levels and insufficient antioxidant levels, while males show mitochondrial lipid oxidative damage. While the reason for this is unclear, it may explain the sex differences in lymphocyte dysfunction we see in PAIS in general. (2/) science.org/doi/10.1126/sc…
ROS-targeting therapies were tested. Metformin treatment in vitro showed some impact on CD4 T cell proliferation. I suspect that other therapies to induce autophagy/mitophagy might also benefit restoration of T cell phenotype. #LowDoseRapamycin 👇🏼 (3/) polybio.org/projects/long-…
Published today! Victoria Bastos, @KerrieGreene_ et al found two distinct immunotypes of ME/CFS based on the cerebrospinal fluid analysis. Great collaboration with @MBVanElzakker @microbeminded2 and the Bragée clinic in Sweden. (1/) academic.oup.com/jimmunol/artic…
This is perfect timing as Victoria will present these data at the @polybioRF symposium today. (2/)
Based on cerebrospinal fluid cytokines, we identified two clusters of ME/CFS patients. Cluster 1 had elevated matrix metalloproteinases & many cytokines compared to cluster 2. Other than older age (Cluster 1), clinical presentation of these clusters was similar. (3/)